Jeff Yass’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.91M Sell
47,100
-24,300
-34% -$838K ﹤0.01% 6572
2026
Q1
$2.25M Buy
71,400
+44,700
+167% +$1.29M ﹤0.01% 5901
2025
Q4
$663K Sell
26,700
-74,800
-74% -$1.5M ﹤0.01% 8158
2025
Q3
$1.65M Buy
101,500
+71,100
+234% +$1.01M ﹤0.01% 6201
2025
Q2
$399K Sell
30,400
-52,000
-63% -$750K ﹤0.01% 9698
2025
Q1
$1.81M Buy
82,400
+18,100
+28% +$475K ﹤0.01% 5748
2024
Q4
$1.72M Sell
64,300
-44,200
-41% -$1.41M ﹤0.01% 5657
2024
Q3
$2.9M Buy
+108,500
New +$2.16M ﹤0.01% 4599

Other funds holding EWTX

Jeff Yass's EWTX Position: Q2 2026 in Review

Jeff Yass reduced its Edgewise Therapeutics (EWTX) stake by 79% in Q2 2026, selling an estimated $723K and leaving 5,692 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #11646.

Jeff Yass first reported a position in EWTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.35M in Q3 2024. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Jeff Yass held 5,692 shares of Edgewise Therapeutics worth $231K as of Q2 2026.
  • Jeff Yass sold 20,982 Edgewise Therapeutics shares in Q2 2026, an estimated $723K.
  • Edgewise Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11646 holding.
  • Jeff Yass first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Jeff Yass's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.